Howard Kaufman, MD - Episode 7

Emerging Agents in the Pipeline for Merkel Cell Carcinoma

EP. 1: The Evolution of Immunotherapy in Cancer
EP. 2: Patient Selection for Checkpoint Inhibitor Therapy and Assessing Response
EP. 3: Emerging Checkpoint Inhibitors and Therapeutic Oncolytic Viruses
EP. 4: Adoptive T-Cell Approaches and Tumor Vaccine Strategies
EP. 5: The Future and the Era of Precision Immunology
EP. 6: Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma
Now Viewing
EP. 7: Emerging Agents in the Pipeline for Merkel Cell Carcinoma
EP. 8: Role of Immunotherapy in Merkel Cell Carcinoma

Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses emerging agents in the pipeline for Merkel cell carcinoma.